{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:48:00Z","timestamp":1779392880241,"version":"3.53.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Estado de Santa Catarina (FAPESC)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study intends to investigate the effect of lithium (Li) and celecoxib (Cel) coadministration on the behavioral status and oxidative stress parameters in a rat model of mania induced by dextroamphetamine (d-AMPH). Male Wistar rats were treated with d-AMPH or saline (Sal) for 14 days; on the 8th day of treatment, rats received lithium (Li), celecoxib (Cel), Li plus Cel, or water until day 14. Levels of oxidative stress parameters were evaluated in the serum, frontal cortex, and hippocampus. d-AMPH administration induced hyperlocomotion in rats, which was significantly reversed by Li and Cel coadministration. In addition, d-AMPH administration induced damage to proteins and lipids in the frontal cortex and hippocampus of rats. All these impairments were reversed by treatment with Li and\/or Cel, in a way dependent on cerebral area and biochemical analysis. Li and Cel coadministration reversed the d-AMPH-induced decrease in catalase activity in cerebral structures. The activity of glutathione peroxidase was decreased in the frontal cortex of animals receiving d-AMPH, and treatment with Li, Cel, or a combination thereof reversed this alteration in this structure. Overall, data indicate hyperlocomotion and alteration in oxidative stress biomarkers in the cerebral structures of rats receiving d-AMPH. Li and Cel coadministration can mitigate these modifications, comprising a potential novel approach for BD therapy.<\/jats:p>","DOI":"10.1038\/s41398-019-0637-9","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T10:03:17Z","timestamp":1573639397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Coadministration of lithium and celecoxib reverses manic-like behavior and decreases oxidative stress in a dopaminergic model of mania induced in rats"],"prefix":"10.1038","volume":"9","author":[{"given":"Samira S.","family":"Valvassori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula T.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo C.","family":"Dal-Pont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Henrique","family":"Cararo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel Freitas","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda F.","family":"Gava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Menegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"637_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1369-7625.2009.00541.x","volume":"12","author":"JG Proudfoot","year":"2009","unstructured":"Proudfoot, J. G. et al. What happens after diagnosis? Understanding the experiences of patients with newly-diagnosed bipolar disorder. Health Expect. 12, 120\u2013129 (2009).","journal-title":"Health Expect."},{"key":"637_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jad.2012.11.033","volume":"147","author":"M Subramaniam","year":"2013","unstructured":"Subramaniam, M. et al. Impact of psychiatric disorders and chronic physical conditions on health-related quality of life: Singapore Mental Health Study. J. Affect. Disord. 147, 325\u2013330 (2013).","journal-title":"J. Affect. Disord."},{"key":"637_CR3","unstructured":"American Psychiatric Association. Bipolar Disorder and Relationship. In American Psychiatric Association (ed). Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). American Psychiatric Press: Washington, DC, 2013, pp 123\u2013155."},{"key":"637_CR4","first-page":"263","volume":"34","author":"AC Andreazza","year":"2009","unstructured":"Andreazza, A. C. et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 34, 263\u2013271 (2009).","journal-title":"J. Psychiatry Neurosci."},{"key":"637_CR5","first-page":"239","volume":"4","author":"RH Belmaker","year":"2004","unstructured":"Belmaker, R. H. & Bersudsky, Y. Bipolar disorder: mania and depression. Discov. Med 4, 239\u2013245 (2004).","journal-title":"Discov. Med"},{"key":"637_CR6","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1590\/1516-4446-2013-1168","volume":"35","author":"SS Valvassori","year":"2013","unstructured":"Valvassori, S. S., Budni, J., Varela, R. B. & Quevedo, J. Contributions of animal models to the study of mood disorders. Rev. Bras. Psiquiatr. 35, S121\u2013S131 (2013).","journal-title":"Rev. Bras. Psiquiatr."},{"key":"637_CR7","first-page":"326","volume":"31","author":"BN Frey","year":"2006","unstructured":"Frey, B. N. et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiatry Neurosci. 31, 326\u2013332 (2006).","journal-title":"J. Psychiatry Neurosci."},{"key":"637_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1399-5618.2006.00318.x","volume":"8","author":"BN Frey","year":"2006","unstructured":"Frey, B. N. et al. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 8, 275\u2013280 (2006).","journal-title":"Bipolar Disord."},{"key":"637_CR9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nn.2647","volume":"13","author":"EJ Nestler","year":"2010","unstructured":"Nestler, E. J. & Hyman, S. E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161\u20131169 (2010).","journal-title":"Nat. Neurosci."},{"key":"637_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1503\/jpn.120257","volume":"39","author":"FY Choi","year":"2014","unstructured":"Choi, F. Y., Ahn, S., Wang, Y. T. & Phillips, A. G. Interference with AMPA receptor endocytosis: effects on behavioural and neurochemical correlates of amphetamine sensitization in male rats. J. Psychiatry Neurosci. 39, 189\u2013199 (2014).","journal-title":"J. Psychiatry Neurosci."},{"key":"637_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jad.2018.10.370","volume":"245","author":"SS Valvassori","year":"2019","unstructured":"Valvassori, S. S. et al. The role of neurotrophic factors in manic-, anxious- and depressive-like behaviors induced by amphetamine sensitization: Implications to the animal model of bipolar disorder. J. Affect. Disord. 245, 1106\u20131113 (2019).","journal-title":"J. Affect. Disord."},{"key":"637_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0269881118812235","volume":"33","author":"D Groos","year":"2018","unstructured":"Groos, D. et al. Chronic antipsychotic treatment targets GIRK current suppression, loss of long-term synaptic depression and behavioural sensitization in a mouse model of amphetamine psychosis. J. Psychopharmacol. 33, 74\u201385 (2018).","journal-title":"J. Psychopharmacol."},{"key":"637_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pnpbp.2018.03.015","volume":"86","author":"AC Issy","year":"2018","unstructured":"Issy, A. C., Dos-Santos-Pereira, M., Pedrazzi, J. F. C., Kubrusly, R. C. C. & Del-Bel, E. The role of striatum and prefrontal cortex in the prevention of amphetamine-induced schizophrenia-like effects mediated by nitric oxide compounds. Prog. Neuropsychopharmacol. Biol. Psychiatry 86, 353\u2013362 (2018).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"637_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yebeh.2017.12.040","volume":"80","author":"A Mishra","year":"2018","unstructured":"Mishra, A., Mishra, A. K. & Jha, S. Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrazole-induced seizures, amphetamine-induced model of schizophrenia, and scopolamine-induced memory loss in laboratory animals. Epilepsy Behav. 80, 144\u2013151 (2018).","journal-title":"Epilepsy Behav."},{"key":"637_CR15","unstructured":"Baldessarini R. J. Drug therapy of depression and anxiety disorders. In Brunton L. L., Lazo J. S., Parker K. L. (eds). Goodman and Gilman\u2019s Pharmacological Basis of Therapeutics, 11th edition. McGraw-Hill: New York, NY, 2006, pp 429\u2013459."},{"key":"637_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1590\/S1516-44462011000100015","volume":"33","author":"E Cheniaux","year":"2011","unstructured":"Cheniaux, E. The pharmacological treatment of bipolar disorder: a systematic and critical review of the methodological aspects of modern clinical trials. Rev. Bras. Psiquiatr. 33, 72\u201380 (2011).","journal-title":"Rev. Bras. Psiquiatr."},{"key":"637_CR17","first-page":"249","volume":"33","author":"AR Rosa","year":"2006","unstructured":"Rosa, A. R., Kapczinski, F., Oliva, R., Stein, A. & Barros, H. M. T. Monitoring the compliance to lithium treatment. Rev. Psiq. Clin. 33, 249\u2013261 (2006).","journal-title":"Rev. Psiq. Clin."},{"key":"637_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","volume":"8","author":"A Whelton","year":"2001","unstructured":"Whelton, A. et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 8, 85\u201395 (2001).","journal-title":"Am. J. Ther."},{"key":"637_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hup.912","volume":"23","author":"FG Nery","year":"2008","unstructured":"Nery, F. G. et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 23, 87\u201394 (2008).","journal-title":"Hum. Psychopharmacol."},{"key":"637_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/bdi.12324","volume":"17","author":"S Arabzadeh","year":"2015","unstructured":"Arabzadeh, S. et al. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord. 17, 606\u2013614 (2015).","journal-title":"Bipolar Disord."},{"key":"637_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biopsych.2013.01.007","volume":"74","author":"A Modabbernia","year":"2013","unstructured":"Modabbernia, A., Taslimi, S., Brietzke, E. & Ashrafi, M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 74, 15\u201325 (2013).","journal-title":"Biol. Psychiatry"},{"key":"637_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000356539","volume":"21","author":"IG Barbosa","year":"2014","unstructured":"Barbosa, I. G., Machado-Vieira, R., Soares, J. C. & Teixeira, A. L. The immunology of bipolar disorder. Neuroimmunomodulation 21, 117\u2013122 (2014).","journal-title":"Neuroimmunomodulation"},{"key":"637_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-45","volume":"10","author":"Kaizaki","year":"2013","unstructured":"Kaizaki et al. Celecoxib reduces brain dopaminergic neuronal dysfunction and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. J. Neuroinflammation 10, 45 (2013).","journal-title":"J. Neuroinflammation"},{"key":"637_CR24","unstructured":"Broadhurst P. L. Experiments in psychogenetics: Application of biometrical genetics to the inheritance of behavior. In Eisenk H. J. (ed). Experiments in Personality: Psychogenetics and psychopharmacology. Routledge & Kegan Paul: London, 1960, pp 31\u201371."},{"key":"637_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0076-6879(94)33040-9","volume":"233","author":"RL Levine","year":"1994","unstructured":"Levine, R. L., Williams, J. A., Stadtman, E. R. & Shacter, E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233, 346\u2013357 (1994).","journal-title":"Methods Enzymol."},{"key":"637_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0076-6879(90)86134-H","volume":"186","author":"H Esterbauer","year":"1990","unstructured":"Esterbauer, H. & Cheeseman, K. H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 186, 407\u2013421 (1990).","journal-title":"Methods Enzymol."},{"key":"637_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0076-6879(84)05016-3","volume":"105","author":"H Aebi","year":"1984","unstructured":"Aebi, H. Catalase in vitro. Methods Enzymol. 105, 121\u2013126 (1984).","journal-title":"Methods Enzymol."},{"key":"637_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0076-6879(81)77046-0","volume":"77","author":"A Wendel","year":"1981","unstructured":"Wendel, A. Glutathione peroxidase. Methods Enzymol. 77, 325\u2013333 (1981).","journal-title":"Methods Enzymol."},{"key":"637_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jpsychires.2010.02.009","volume":"44","author":"SS Valvassori","year":"2010","unstructured":"Valvassori, S. S. et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J. Psychiatr. Res. 44, 903\u2013909 (2010).","journal-title":"J. Psychiatr. Res."},{"key":"637_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bdi.12299","volume":"17","author":"SS Valvassori","year":"2015","unstructured":"Valvassori, S. S. et al. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disord. 17, 507\u2013517 (2015).","journal-title":"Bipolar Disord."},{"key":"637_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pbb.2019.05.009","volume":"183","author":"Samira S. Valvassori","year":"2019","unstructured":"Valvassori S. S. et al. Coadministration of lithium and celecoxib attenuates the behavioral alterations and inflammatory processes induced by amphetamine in an animal model of mania. Pharmacol. Biochem. Behav. 183, 56\u201363 (2019).","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"637_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbr.2012.07.007","volume":"234","author":"Y Borre","year":"2012","unstructured":"Borre, Y. et al. Celecoxib delays cognitive decline in an animal model of neurodegeneration. Behav. Brain Res. 234, 285\u2013291 (2012).","journal-title":"Behav. Brain Res."},{"key":"637_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0014-2999(02)02104-0","volume":"450","author":"BM Ross","year":"2002","unstructured":"Ross, B. M. et al. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur. J. Pharm. 450, 141\u2013151 (2002).","journal-title":"Eur. J. Pharm."},{"key":"637_CR34","doi-asserted-by":"publisher","first-page":"10116","DOI":"10.1523\/JNEUROSCI.2368-07.2007","volume":"27","author":"M Mizuno","year":"2007","unstructured":"Mizuno, M. et al. A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. J. Neurosci. 27, 10116\u201310127 (2007).","journal-title":"J. Neurosci."},{"key":"637_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-1-6","volume":"1","author":"S\u00e1nchez-Pernaute","year":"2004","unstructured":"S\u00e1nchez-Pernaute et al. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson\u2019s disease. J. Neuroinflammation 1, 6 (2004).","journal-title":"J. Neuroinflammation"},{"key":"637_CR36","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1523\/JNEUROSCI.19-04-01484.1999","volume":"19","author":"MJ LaVoie","year":"1999","unstructured":"LaVoie, M. J. & Hastings, T. G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. J. Neurosci. 19, 1484\u20131491 (1999).","journal-title":"J. Neurosci."},{"key":"637_CR37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1471-4159.2008.05421.x","volume":"106","author":"DM Thomas","year":"2008","unstructured":"Thomas, D. M., Francescutti-Verbeem, D. M. & Kuhn, D. M. Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. J. Neurochem. 106, 696\u2013705 (2008).","journal-title":"J. Neurochem."},{"key":"637_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0022-3956(99)00007-2","volume":"33","author":"MH Rapaport","year":"1999","unstructured":"Rapaport, M. H., Guylai, L. & Whybrow, P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J. Psychiatr. Res. 33, 335\u2013340 (1999).","journal-title":"J. Psychiatr. Res."},{"key":"637_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1749-6632.2009.05141.x","volume":"1187","author":"BK Yamamoto","year":"2010","unstructured":"Yamamoto, B. K., Moszczynska, A. & Gudelsky, G. A. Amphetamine toxicities: classical and emerging mechanisms. Ann. NY Acad. Sci. 1187, 101\u2013121 (2010).","journal-title":"Ann. NY Acad. Sci."},{"key":"637_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuint.2013.07.003","volume":"63","author":"HM Wang","year":"2013","unstructured":"Wang, H. M. et al. Inhibition of glycogen synthase kinase-3\u03b2 by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochem. Int. 63, 345\u2013353 (2013).","journal-title":"Neurochem. Int."},{"key":"637_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lfs.2016.08.027","volume":"163","author":"EM ELnahas","year":"2016","unstructured":"ELnahas, E. M., Zeid, M. S., Kawy, H. S., Hendawy, N. & Baher, W. Celecoxib attenuates depressive-like behavior associated with immunological liver injury in C57BL\/6 mice through TNF-\u03b1 and NF-\u03bab dependent mechanisms. Life Sci. 163, 23\u201337 (2016).","journal-title":"Life Sci."},{"key":"637_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.pbb.2012.09.010","volume":"103","author":"G Feier","year":"2013","unstructured":"Feier, G. et al. Lithium and valproate modulate energy metabolism in an animal model of mania induced by methamphetamine. Pharm. Biochem. Behav. 103, 589\u2013596 (2013).","journal-title":"Pharm. Biochem. Behav."},{"key":"637_CR43","first-page":"516","volume":"33","author":"AC Andreazza","year":"2008","unstructured":"Andreazza, A. C. et al. Effects of mood stabilizers on DNA damage in an animal model of mania. J. Psychiatry Neurosci. 33, 516\u2013524 (2008).","journal-title":"J. Psychiatry Neurosci."},{"key":"637_CR44","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/0269881112463124","volume":"26","author":"K Cechinel-Recco","year":"2012","unstructured":"Cechinel-Recco, K. et al. Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. J. Psychopharmacol. 26, 1594\u20131604 (2012).","journal-title":"J. Psychopharmacol."},{"issue":"2 Suppl 1","key":"637_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0026-0495(00)80077-3","volume":"49","author":"DJ Betteridge","year":"2000","unstructured":"Betteridge, D. J. What is oxidative stress? Metabolism 49(2 Suppl 1), 3\u20138 (2000).","journal-title":"Metabolism"},{"key":"637_CR46","first-page":"113","volume":"4","author":"EY Osman","year":"2016","unstructured":"Osman, E. Y. Effects of celecoxib or omega-3 fatty acids alone and in combination with risperidone on the behavior and brain biochemistry in amphetamine-induced model of schizophrenia. Pharm. Bioprocess 4, 113\u2013125 (2016).","journal-title":"Pharm. Bioprocess"},{"key":"637_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/appi.ajp.157.5.683","volume":"157","author":"Z Kronfol","year":"2000","unstructured":"Kronfol, Z. & Remick, D. G. Cytokines and the brain: Implications for clinical psychiatry. Am. J. Psychiatry 157, 683\u2013694 (2000).","journal-title":"Am. J. Psychiatry"},{"key":"637_CR48","first-page":"240","volume":"7","author":"J Venugopal","year":"2015","unstructured":"Venugopal, J. & Prakash, R. Protective effect of COX inhibitors on lipopolysaccharide-induced sickness behaviour or neuroinflammation and oxidative stress on male Wistar rats. Int J. Pharm. Pharm. Sci. 7, 240\u2013245 (2015).","journal-title":"Int J. Pharm. Pharm. Sci."},{"key":"637_CR49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.59566\/IJBS.2007.3176","volume":"3","author":"M Kuhar","year":"2007","unstructured":"Kuhar, M., Imran, S. & Singh, N. Celecoxib enhances the chemotherapeutic response of cisplatin and TNF-\u03b1 in SiHa cells through reactive oxygen species-mediated mitochondrial pathway. Int J. Biomed. Sci. 3, 176\u2013184 (2007).","journal-title":"Int J. Biomed. Sci."},{"key":"637_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00702-011-0691-9","volume":"119","author":"DD da-Rosa","year":"2012","unstructured":"da-Rosa, D. D. et al. Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats. J. Neural. Transm. (Vienna) 119, 31\u201338 (2012).","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"637_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/1389557515666150324122026","volume":"15","author":"E Callaly","year":"2015","unstructured":"Callaly, E. et al. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev. Med. Chem. 15, 355\u2013365 (2015).","journal-title":"Mini Rev. Med. Chem."},{"key":"637_CR52","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/NDT.S106479","volume":"12","author":"L Dell\u2019Osso","year":"2016","unstructured":"Dell\u2019Osso, L., Del Grande, C., Gesi, C., Carmassi, C. & Musetti, L. A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr. Dis. Treat. 12, 1687\u20131703 (2016).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"637_CR53","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.pnpbp.2013.01.007","volume":"43","author":"DS Mac\u00eado","year":"2013","unstructured":"Mac\u00eado, D. S. et al. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 43, 230\u2013237 (2013).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"637_CR54","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jpsychires.2006.07.013","volume":"41","author":"AC Andreazza","year":"2007","unstructured":"Andreazza, A. C. et al. Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 41, 523\u2013529 (2007).","journal-title":"J. Psychiatr. Res."},{"key":"637_CR55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-009-1031-8","volume":"65","author":"AL Bastos-Pereira","year":"2010","unstructured":"Bastos-Pereira, A. L. et al. Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. Cancer Chemother. Pharm. 65, 267\u2013276 (2010).","journal-title":"Cancer Chemother. Pharm."},{"key":"637_CR56","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.4088\/JCP.v64n1108","volume":"64","author":"KM Phelan","year":"2003","unstructured":"Phelan, K. M., Mosholder, A. D. & Lu, S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J. Clin. Psychiatry 64, 1328\u20131334 (2003).","journal-title":"J. Clin. Psychiatry"},{"key":"637_CR57","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1345\/aph.1E034","volume":"38","author":"AE R\u00e4tz Bravo","year":"2004","unstructured":"R\u00e4tz Bravo, A. E., Egger, S. S., Crespo, S., Probst, W. L. & Kr\u00e4henb\u00fchl, S. Lithium intoxication as a result of an interaction with rofecoxib. Ann. Pharmacother. 38, 1189\u20131193 (2004).","journal-title":"Ann. Pharmacother."},{"key":"637_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","volume":"53","author":"JD Rosenblat","year":"2014","unstructured":"Rosenblat, J. D., Cha, D. S., Mansur, R. B. & McIntyre, R. S. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 53, 23\u201334 (2014).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"637_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pnpbp.2016.09.004","volume":"72","author":"J Data-Franco","year":"2017","unstructured":"Data-Franco, J. et al. Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. Prog. Neuropsychopharmacol. Biol. Psychiatry 72, 73\u201386 (2017).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"637_CR60","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/14737159.2016.1248413","volume":"16","author":"AL Teixeira","year":"2016","unstructured":"Teixeira, A. L., Salem, H., Frey, B. N., Barbosa, I. G. & Machado-Vieira, R. Update on bipolar disorder biomarker candidates. Expert Rev. Mol. Diagn. 16, 1209\u20131220 (2016).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"637_CR61","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1089\/cap.2016.0207","volume":"27","author":"SY Mousavi","year":"2017","unstructured":"Mousavi, S. Y. et al. A randomized, double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania. J. Child Adolesc. Psychopharmacol. 27, 494\u2013500 (2017).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"637_CR62","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.4088\/JCP.08r04505","volume":"70","author":"BI Goldstein","year":"2009","unstructured":"Goldstein, B. I., Kemp, D. E., Soczynska, J. K. & McIntyre, R. S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70, 1078\u20131090 (2009).","journal-title":"J. Clin. Psychiatry"},{"key":"637_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2014.12.015","volume":"174","author":"Z Ayorech","year":"2015","unstructured":"Ayorech, Z., Tracy, D. K., Baumeister, D. & Giaroli, G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J. Affect. Disord. 174, 467\u2013478 (2015).","journal-title":"J. Affect. Disord."},{"key":"637_CR64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pnpbp.2012.06.003","volume":"39","author":"D Johansson","year":"2012","unstructured":"Johansson, D., Falk, A., Marcus, M. M. & Svensson, T. H. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 143\u2013148 (2012).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0637-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0637-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0637-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:08:32Z","timestamp":1722028112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0637-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0637-9","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"4 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JQ has the following disclosures: I. Clinical Research Support: Janssen Pharmaceutical (Clinical Trial), Allergan (Clinical Trial) II. Advisory Boards, Speaker Bureaus, Expert Witness, or Consultant Daiichi Sankyo (Speaker Bureau) III. Patent, Equity, or Royalty Instituto de Neurociencias Dr. Joao Quevedo (Stockholder) IV. Other Artmed Editora (Copyright), Artmed Panamericana (Copyright).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"297"}}